Literature DB >> 33502336

Differential activity and expression of human 5β-reductase (AKR1D1) splice variants.

Nathan Appanna1, Hylton Gibson2, Elena Gangitano1,3, Niall J Dempster1, Karen Morris4, Sherly George4, Anastasia Arvaniti1,5, Laura L Gathercole1,5, Brian Keevil4, Trevor M Penning6, Karl-Heinz Storbeck2, Jeremy W Tomlinson1, Nikolaos Nikolaou1.   

Abstract

Steroid hormones, including glucocorticoids and androgens, exert a wide variety of effects in the body across almost all tissues. The steroid A-ring 5β-reductase (AKR1D1) is expressed in human liver and testes, and three splice variants have been identified (AKR1D1-001, AKR1D1-002, AKR1D1-006). Amongst these, AKR1D1-002 is the best described; it modulates steroid hormone availability and catalyses an important step in bile acid biosynthesis. However, specific activity and expression of AKR1D1-001 and AKR1D1-006 are unknown. Expression of AKR1D1 variants were measured in human liver biopsies and hepatoma cell lines by qPCR. Their three-dimensional (3D) structures were predicted using in silico approaches. AKR1D1 variants were overexpressed in HEK293 cells, and successful overexpression confirmed by qPCR and Western blotting. Cells were treated with either cortisol, dexamethasone, prednisolone, testosterone or androstenedione, and steroid hormone clearance was measured by mass spectrometry. Glucocorticoid and androgen receptor activation were determined by luciferase reporter assays. AKR1D1-002 and AKR1D1-001 are expressed in human liver, and only AKR1D1-006 is expressed in human testes. Following overexpression, AKR1D1-001 and AKR1D1-006 protein levels were lower than AKR1D1-002, but significantly increased following treatment with the proteasomal inhibitor, MG-132. AKR1D1-002 efficiently metabolised glucocorticoids and androgens and decreased receptor activation. AKR1D1-001 and AKR1D1-006 poorly metabolised dexamethasone, but neither protein metabolised cortisol, prednisolone, testosterone or androstenedione. We have demonstrated the differential expression and role of AKR1D1 variants in steroid hormone clearance and receptor activation in vitro. AKR1D1-002 is the predominant functional protein in steroidogenic and metabolic tissues. In addition, AKR1D1-001 and AKR1D1-006 may have a limited, steroid-specific role in the regulation of dexamethasone action.

Entities:  

Keywords:  cortisol; dexamethasone; liver; steroids; testosterone

Mesh:

Substances:

Year:  2021        PMID: 33502336      PMCID: PMC7965358          DOI: 10.1530/JME-20-0160

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  45 in total

1.  Detection and characterization of prednisolone metabolites in human urine by LC-MS/MS.

Authors:  Xavier Matabosch; Oscar J Pozo; Clara Pérez-Mañá; Esther Papaseit; Jordi Segura; Rosa Ventura
Journal:  J Mass Spectrom       Date:  2015-03       Impact factor: 1.982

Review 2.  Therapeutic Mechanisms of Glucocorticoids.

Authors:  Jolien Vandewalle; Astrid Luypaert; Karolien De Bosscher; Claude Libert
Journal:  Trends Endocrinol Metab       Date:  2017-11-20       Impact factor: 12.015

3.  Substrate specificity and inhibitor analyses of human steroid 5β-reductase (AKR1D1).

Authors:  Mo Chen; Jason E Drury; Trevor M Penning
Journal:  Steroids       Date:  2011-01-19       Impact factor: 2.668

4.  N-terminal degradation activates the NLRP1B inflammasome.

Authors:  Ashley J Chui; Marian C Okondo; Sahana D Rao; Kuo Gai; Andrew R Griswold; Darren C Johnson; Daniel P Ball; Cornelius Y Taabazuing; Elizabeth L Orth; Brooke A Vittimberga; Daniel A Bachovchin
Journal:  Science       Date:  2019-03-14       Impact factor: 47.728

5.  Crystal structures of human Delta4-3-ketosteroid 5beta-reductase (AKR1D1) reveal the presence of an alternative binding site responsible for substrate inhibition.

Authors:  Frédérick Faucher; Line Cantin; Van Luu-The; Fernand Labrie; Rock Breton
Journal:  Biochemistry       Date:  2008-12-23       Impact factor: 3.162

6.  Cloning and expression of cDNA of human delta 4-3-oxosteroid 5 beta-reductase and substrate specificity of the expressed enzyme.

Authors:  K H Kondo; M H Kai; Y Setoguchi; G Eggertsen; P Sjöblom; T Setoguchi; K I Okuda; I Björkhem
Journal:  Eur J Biochem       Date:  1994-01-15

7.  Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation.

Authors:  D M Gentile; E S Tomlinson; J L Maggs; B K Park; D J Back
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

Review 8.  The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects.

Authors:  Marlies C van der Goes; Johannes W Jacobs; Johannes W Bijlsma
Journal:  Arthritis Res Ther       Date:  2014-11-13       Impact factor: 5.156

9.  Bile acid homeostasis controls CAR signaling pathways in mouse testis through FXRalpha.

Authors:  Emmanuelle Martinot; Marine Baptissart; Aurélie Véga; Lauriane Sèdes; Betty Rouaisnel; Fred Vaz; Jean-Paul Saru; Angélique de Haze; Silvère Baron; Françoise Caira; Claude Beaudoin; David H Volle
Journal:  Sci Rep       Date:  2017-02-09       Impact factor: 4.379

10.  Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Jamie L Renbarger; Zeina M Nabhan; Sydney E Ross; James E Slaven; Lang Li; Emily C Walvoord; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2016-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.